S&CO Inc. Holds Stake in Amgen Inc. (AMGN)

S&CO Inc. continued to hold its stake in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 18,600 shares of the medical research company’s stock at the end of the 2nd quarter. S&CO Inc.’s holdings in Amgen were worth $3,203,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Camelot Portfolios LLC acquired a new stake in Amgen in the 1st quarter valued at approximately $1,429,000. PGGM Investments increased its holdings in Amgen by 2.3% in the 2nd quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock valued at $115,555,000 after purchasing an additional 15,059 shares during the last quarter. Shelton Capital Management increased its holdings in Amgen by 82.7% in the 1st quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock valued at $17,883,000 after purchasing an additional 49,354 shares during the last quarter. Greylin Investment Mangement Inc. increased its holdings in Amgen by 466.9% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock valued at $2,416,000 after purchasing an additional 11,555 shares during the last quarter. Finally, Kelman Lazarov Inc. increased its holdings in Amgen by 8.2% in the 2nd quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 120 shares during the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.

Several analysts recently weighed in on AMGN shares. Cann reiterated a “buy” rating on shares of Amgen in a report on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 target price on shares of Amgen in a report on Thursday, September 7th. Deutsche Bank AG started coverage on shares of Amgen in a report on Friday, June 23rd. They issued a “hold” rating and a $172.00 target price for the company. William Blair reiterated a “market perform” rating on shares of Amgen in a report on Monday, June 26th. Finally, Mizuho reiterated a “buy” rating and issued a $198.00 target price (up previously from $183.00) on shares of Amgen in a report on Thursday, September 28th. Ten analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $189.99.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.19% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/10/11/sco-inc-holds-stake-in-amgen-inc-amgn.html.

Shares of Amgen Inc. (NASDAQ AMGN) opened at 185.79 on Wednesday. The stock has a market capitalization of $135.57 billion, a PE ratio of 16.92 and a beta of 1.36. The company has a 50-day moving average of $182.35 and a 200-day moving average of $170.56. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same period in the prior year, the firm posted $2.84 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts expect that Amgen Inc. will post $12.58 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply